SOURCE: Health Discovery Corporation

April 27, 2005 08:00 ET

Health Discovery Corporation Announces Issuance of New U.S. Patent Covering Use of SVMs for Processing Multiple Data Sets

SAVANNAH, GA -- (MARKET WIRE) -- April 27, 2005 -- Health Discovery Corporation (OTC BB: HDVY) is pleased to announce that the U.S. Patent and Trademark Office has issued Patent No. 6,882,990. This patent covers methods for using multiple support vector machines (SVMs) for processing multiple sets of biological data. These methods are particularly relevant to diagnostic and therapeutic applications in which diverse data types, such as gene expression data, proteomic data, clinical data, and medical images, are generated for evaluation of diseases and conditions.

Traditionally, each diverse data type must be evaluated separately. The results of each evaluation are then combined by human intervention, in which a researcher or physician reviews the individual test results to generate an overall conclusion. Such processes are prone to human error and personal biases, which often leads to erroneous or inconsistent conclusions. Using the claimed invention in Health Discovery Corporation's newly issued patent, the complete analysis can be performed in a computer-based process in which a first layer of optimized SVMs is used to analyze the different types of input data. The results are then combined and automatically re-entered into an optimized second SVM that generates a more accurate single result using the acquired knowledge from the original diverse input data.

In addition to this new patent, Health Discovery Corporation's SVM patent portfolio alone includes 12 issued and over 35 pending U.S. and foreign patents covering applications of support vector machines for discovery of knowledge from large data sets.

The issued patents in this patent portfolio cover methods and systems for pre-processing of data to enhance knowledge discovery using SVMs, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet. Health Discovery Corporation's pending U.S. and foreign patent applications cover numerous improvements to and applications of SVMs, including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images for circulating tumor cells and digital mammography, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, leukemia, prostate cancer and renal cancer discovered with these methods, and use of SVMs for analysis of spectral data such as data generated in mass spectrometry.

Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, commented, "We are thrilled to add yet another issued patent to our very mature and extensive portfolio of SVM patents. This accomplishment further solidifies our position as a leader in the development and implementation of this world recognized state-of-the-art technology." Dr. Barnhill continued, "I am extremely honored to have Dr. Vladimir Vapnik and Dr. Isabelle Guyon, co-inventors of the SVM, as members of Health Discovery Corporation's Scientific Team. Their continued efforts on our behalf will assure that our Company will remain in the forefront of mathematical invention, which is critical to accurate biomarker discovery for new diagnostic tests and safer drugs as we move into the era of personalized medicine."

Health Discovery Corporation is a systems biology-oriented biomarker and pathway discovery company, which provides all aspects of First-Phase Biomarker Discovery(SM). The Company was established to provide pharmaceutical and diagnostic companies worldwide with newly discovered biomarkers used to create more accurate diagnostic tests, novel drug targets for more personalized medicines and new methods for detecting patients "at-risk" for toxicity-related events, thereby providing safer medications. Founded in September 2003, the Company is headquartered in Savannah, GA. For further information contact Stephen D. Barnhill, M.D., at

This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

Contact Information